Suppliers and packagers for generic pharmaceutical drug: SONIDEGIB PHOSPHATE

SONIDEGIB PHOSPHATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sun Pharm	ODOMZO	sonidegib phosphate	CAPSULE;ORAL	205266	NDA	Sun Pharmaceutical Industries, Inc.	47335-303-15	30 CAPSULE in 1 BOTTLE (47335-303-15)	2017-09-21
Sun Pharm	ODOMZO	sonidegib phosphate	CAPSULE;ORAL	205266	NDA	Sun Pharmaceutical Industries, Inc.	47335-303-83	30 CAPSULE in 1 BOTTLE (47335-303-83)	2017-09-21

Suppliers and packagers for generic pharmaceutical drug: SONIDEGIB PHOSPHATE

Last updated: May 26, 2026

Suppliers for Sonidegib Phosphate (API, Intermediates, Contract Manufacturing)

Sonidegib phosphate supply is centered on a small number of capable API manufacturers plus specialized intermediate producers for the HSP90 pathway inhibitor scaffold. In practice, buyers typically qualify either (1) finished-sonidegib phosphate API suppliers with complete DMF dossiers for global registration or (2) contract manufacturers that can supply GMP drug substance and scale proven synthesis routes from key intermediates.

Which companies supply sonidegib phosphate API and drug substance globally?

Sonidegib phosphate is marketed as a drug substance derived from the sonidegib (free base) API and converted to the phosphate salt. Supplier selection in pharma supply chains depends on whether the vendor can provide: GMP sonidegib phosphate API, regulatory support (DMF/ASMF), and a reproducible salt-form conversion process.

Common supplier profiles

• API manufacturers: sell sonidegib (as free base) and/or sonidegib phosphate under GMP with documentation suitable for registration dossiers.
• Intermediate suppliers: provide advanced intermediates used in the sonidegib route, often needed for dual-sourcing or cost-down.
• CDMOs for conversion to phosphate salt: handle salt formation, filtration, drying, and particle-control steps that affect solubility and stability.

What buyers should check in vendor qualification

• GMP status for drug substance (not only intermediates)
• DMF/ASMF availability for the exact salt form (phosphate)
• demonstrated control of salt form identity (phosphate stoichiometry, polymorph control if applicable)
• analytical package consistency (HPLC assay, water content, residual solvents, inorganic impurities)
• supply continuity for scale-up (kg to multi-ton capability across batches)

What intermediates are typically used to make sonidegib phosphate, and who supplies them?

Sonidegib phosphate is produced via a multi-step synthesis of the sonidegib core, then conversion to the phosphate salt. Upstream intermediate vendors usually supply one or more of the following categories (terminology varies by route and vendor):

• Core heterocycle building blocks (aryl/heteroaryl fragments)
• Amine and linker intermediates used to assemble the final scaffold
• Final-stage precursors that feed the last API-forming steps
• Salt-form conversion inputs, including standardized phosphoric acid sources and quality-controlled salts used to ensure consistent conversion

Supplier sourcing strategy

• Dual-source at the intermediate level (reduce single-point risk).
• Require a process-relevant impurity map from the intermediate supplier for downstream risk control.
• Use phosphate salt conversion vendors only if they can demonstrate comparability versus the drug substance used in pivotal studies.

Do suppliers offer sonidegib base or only sonidegib phosphate, and how does this change sourcing?

Many suppliers commercialize the free base, while the phosphate salt is produced for the finished drug substance. This means sourcing can bifurcate:

• If the supplier sells sonidegib base: the buyer must either convert to phosphate in-house or outsource salt formation to a CDMO with a validated conversion protocol.
• If the supplier sells sonidegib phosphate: procurement is simpler, but the buyer must verify the phosphate form used is the same as that supported in regulatory filings and clinical material.

Operational impact

• Salt conversion introduces extra controls (filterability, hygroscopicity, residual solvent/water, phosphate content).
• Procurement lead times can shift based on whether phosphate conversion happens at the supplier site or after shipment.

What regulatory documentation do sonidegib phosphate suppliers provide (DMF, CEP, CoA)?

For international development and supply, buyers typically require:

• DMF or ASMF support aligned to the exact form (phosphate)
• GMP certificates covering manufacturing sites and dosage-form scope (for drug substance)
• Certificates of Analysis (CoA) for each batch including identity tests for phosphate salt form
• Stability data supporting shelf-life for the packaged form used by the buyer
• Residual solvent and impurity controls per ICH Q3A/Q3B approaches

Key dossier checks

• whether the regulatory filing references sonidegib phosphate specifically
• whether there is a documented salt-form control strategy
• whether the impurity profile covers conversion-related impurities (and not only the free base synthesis)

How do contract manufacturing organizations (CMOs) source and produce sonidegib phosphate?

CMOs/CDMOs usually operate via:

• A qualified API route with internal intermediate production or purchased key intermediates
• Salt formation using a controlled workflow:
  • standardized phosphoric acid feed
  • pH and solvent system management
  • temperature profile control
  • filtration and washing steps tuned to phosphate crystallization
  • drying under controlled humidity and temperature
• Batch release with an analytical panel suited to phosphate salt confirmation

What to require from CDMOs

• process validation package (PPQ) for the salt conversion step
• comparability report between lab, pilot, and GMP lots
• impurity control strategy specifically addressing salt-form conversion effects

What sourcing risks exist for sonidegib phosphate (single-source, polymorph, salt conversion)?

The primary supply risks are not generic to all API products, but they matter operationally here:

• Single-source dependence on a vendor that uniquely controls the salt-form
• Variability in phosphate salt properties across batches, affecting downstream formulation performance
• Conversion yield and impurity shifts introduced by changes in solvent systems or phosphoric acid grade
• Lead-time shocks from intermediate bottlenecks in multi-step synthesis routes

Mitigation

• Qualify at least one alternate intermediate supply chain.
• Validate phosphate conversion comparability if any supplier change occurs at the free base stage.
• Ensure vendor change notifications include process-critical parameters.

How strong is the supplier landscape for sonidegib phosphate versus other SMO inhibitors (comparative sourcing)?

Sonidegib is in the hedgehog pathway inhibitor class alongside other SMO inhibitors. From a supply-chain standpoint, the differentiators are:

• complexity of the final scaffold synthesis
• whether the market standard is free base versus specific salt forms
• whether major suppliers already maintain registration-ready DMF packages for the salt form

In practice, buyers often find:

• fewer qualified suppliers for registered phosphate salt than for free base
• more CDMO capacity for salt formation than for full scaffold synthesis

What commercial considerations drive supplier selection for sonidegib phosphate?

Supplier selection is driven by:

• capacity to support scale-up
• ability to supply on forecasted cadence (not only large one-off lots)
• regulatory readiness (DMF/ASMF support and document turnaround)
• pricing structure linked to intermediates and salt-form conversion complexity
• responsiveness for tech transfer and change control

Procurement “must haves”

• batch traceability to manufacturing steps for phosphate conversion
• CoA release aligned to buyer specification limits
• stable supply chain for phosphoric acid and key intermediates used in last-stage synthesis

What should buyers ask suppliers of sonidegib phosphate during qualification?

Qualification typically focuses on:

• the exact material definition: “sonidegib phosphate” with salt-form confirmation
• GMP manufacturing site details and certification scope
• impurity specification acceptance and analytical methods
• stability program coverage for the buyer’s packaging configuration
• documented change control history, including any previous salt conversion process adjustments

Key Takeaways

• Sonidegib phosphate supply is usually fragmented between API manufacturers and specialized salt conversion capacity.
• Supplier qualification depends on whether the vendor provides GMP sonidegib phosphate with DMF/ASMF support for the salt form, not just sonidegib free base.
• The main supply risk centers on phosphate salt conversion consistency and intermediate bottlenecks.
• Buyers typically reduce risk via dual-sourcing at key intermediate points and verifying phosphate comparability if sourcing shifts.

FAQs

1) Can sonidegib phosphate be sourced as sonidegib free base and converted to phosphate in a CDMO?
Yes, but qualification requires demonstrated salt-form comparability, including phosphate identity controls and impurity impact from the conversion step.

2) What documentation matters most when selecting a sonidegib phosphate API supplier for global filings?
DMF/ASMF coverage specific to sonidegib phosphate, GMP scope for the manufacturing site, and a full batch analytical package with phosphate confirmation.

3) Are suppliers of sonidegib phosphate limited compared with other API salts?
Salt-form-specific capability is typically more constrained than free base supply, and fewer vendors maintain regulator-ready documentation for the exact phosphate salt.

4) What is the biggest technical risk in switching sonidegib phosphate suppliers?
Differences in salt-form conversion parameters that change crystal properties and can shift impurity profiles.

5) Do intermediate suppliers need to support impurity profiles for downstream sonidegib phosphate manufacture?
Yes. Downstream control depends on knowing process-relevant impurities from intermediates and how they propagate to the final API.

References

1. ICH Q3A(R2). Impurities in New Drug Substances.
2. ICH Q3B(R2). Impurities in New Drug Products.
3. ICH Q6A. Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.
4. FDA. Guidance for Industry: DMF Requirements (as applicable to API submissions).
5. EMA. Guidance on Certificates of Suitability and DMF/ASMF-type documentation (as applicable).